Bile Acid Diarrhea (BAD)
The phase II proof-of-concept-study for Bile Acid Diarrhea was approved in the UK at the end of 2024, with the first clinical site activation underway. The first patient is expected to be enrolled by the end of January 2025. BAD affects an estimated 95 million people globally, with studies suggesting that approximately 30% of patients with Irritable Bowel Syndrome with Diarrhea (IBS-D) suffer from BAD.
Distal Ulcerative Colitis (Distal UC)
The phase II study for Distal Ulcerative Colitis is progressing, with active patient recruitment across 24 sites. Distal UC affects an estimated 3.5 million people globally, with studies indicating that approximately 70% of Ulcerative Colitis patients experience Distal UC.
Solid Tumors
An ongoing Phase I study evaluating the safety and efficacy of treatments for solid tumors is progressing well. Following the completion of Part I of the study in H2 2025, Cosmo plans to explore partnership opportunities for this asset to align its R&D portfolio with strategic priorities.
Leadership and Strategic Growth
Giovanni Di Napoli, CEO of Cosmo, highlighted 2024 as a transformative year for the company, marked by innovation, achievement, and significant progress. The company has strengthened its foundation for future success through strategic investments, operational excellence, and fostering a culture of collaboration. Svetlana Sigalova, CFO, emphasized the company's robust cash position and debt-free balance sheet as enabling factors for advancing its pipeline and delivering value to patients and shareholders.
Cosmo Pharmaceuticals N.V., headquartered in Dublin, Ireland, with offices in San Diego, USA, and Lainate/Rome/Catania, Italy, is committed to revolutionizing healthcare and transforming people’s lives through innovative products that address unfulfilled healthcare demands. The company collaborates with leading partners worldwide for the commercialization and distribution of its products.
